VERONA PHARMA P / S was downgraded from a “buy” rating to a “sell” rating by Zacks Investment Research in a research report published on Saturday, informs Zacks.com.
Several other stock analysts have released company reports. In a research report on Thursday, August 1, ValuEngine lifted VERONA PHARMA P / S from a “sell” rating to a “buy” rating.
NASDAQ: VRNA traded down $0.09 on Friday, reaching $4.25 during trading hours. Compared with its average volume of 4,327, the company had a trading volume of 6,200 shares. The stock has a moving 50-day average of $4.35 and a moving 200-day average of $4.93. The business has a debt-to-equity ratio of 0.02, a current 4.07 ratio, and a rapid 4.07 ratio. The firm has a $58.83 million market capitalization, a -2.10 PE ratio and a -0.98 beta. VERONA PHARMA P / S has $3.65 for 52 weeks and $12.50 for 52 weeks.
Recently a hedge fund boosted its stake in stock of VERONA PHARMA P / S. According to its most recent 13F filing with the Securities & Exchange Commission, Wedbush Securities Inc. increased its holdings in shares of VERONA PHARMA P / S (NASDAQ: VRNA) by 24.7% in the third quarter. After purchasing a further 6,000 shares during the period, the fund owned 30,315 shares of the company’s stock. As of its most recent filing with the Securities & Exchange Commission, Wedbush Securities Inc. owned approximately 0.23% of VERONA PHARMA P / S worth $139,000. Corporate investors currently own 56.02 percent of the stock.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a biopharmaceutical company in the clinical stage, develops and sells therapies for the treatment of respiratory diseases. The company’s product candidate is RPL554, an inhaled dual inhibitor of phosphodiesterase 3 as well as 4 enzymes, which has undergone Phase I and II clinical trials as a bronchodilator and anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma and allergic rhinitis.